Amanda Nizam, MD
@amandanizammd
GU Medical Oncologist @ClevelandClinic | Bladder, kidney, & prostate Ca | Tx-related toxicity | @ASCOTECAG & @GWSMHS alum | 🌎 citizen | Views my own | COI ⬇️
ID: 106342723
https://coi.asco.org/share/VF7-WR44/Amanda%20Nizam 19-01-2010 07:22:54
4,4K Tweet
1,1K Followers
1,1K Following
Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…
Out today in TIME — a review of recent advances in #KidneyCancer treatment highlighting the incredible work of Toni Choueiri, MD Dana-Farber Lank Center for Genitourinary Oncology Brian Rini, MD Vanderbilt Hem / Onc william huang nyulmc Katie Spina (she/her) Columbia RadOnc George R Schade Fred Hutchinson Cancer Center and many others! It takes a village to
Thank you to Society for Immunotherapy of Cancer and Melanoma Research for supporting our research!
Out in Journal of Clinical Oncology our next piece of the neoadjuvant puzzle in muscle-invasive #bladdercancer. Taxanes could be another good choice of backbone chemo to combine with IO, overcoming the known limits of platinum. #NureCombo provided Nivo/ABX x4 > RC > adj Nivo x13. N=31. 22 pts
Grateful for 8 wonderful years at the Cleveland Clinic Cleveland Clinic Lerner Research Institute. I will miss my amazing colleagues. So excited for the next adventure at Fred Hutchinson Cancer Center University of Washington Radiation Oncology!
☢️ Systematic review and meta-analysis of SABR in oligoprogression published in Radiotherapy & Oncology authors.elsevier.com/c/1jkuTcA0-IX1E Joelle Dr. David Palma Aisling Barry Jacques Raphael
Just in The Lancet Oncology 👉Zr-girentuximab PET–CT is highly accurate for detecting ccRCC #kidneycancer (like PSMA-PET in prostate ca) Congrats, Brian Brian Shuch, MD et al, on these practice-impacting data. Open access👉tinyurl.com/4cwkm8u5 Michael Morris OncoAlert UroToday.com
Paper out- TLX-250cdx as a tool to help patients with renal masses! also excited to have high risk postop staging protocol open too (Canine). UCLA Urology . Kidney Cancer KCCure KidneyCAN Kidney Cancer Canada YUO thelancet.com/journals/lanon… clinicaltrials.gov/study/NCT06447…
🚨 Start prepping for #ESMO2024 with half of TwoOncDocs Samantha Armstrong's round-up of #abstracts to keep an eye on in the #prostatecancer #UC, #MIBC, and #RCC spaces. 👀 Read more: buff.ly/4cZzFdN
Congrats to Pedro C Barata, MD MSc FACP Sumanta K. Pal, MD, FASCO and the entire team for the final OS analysis from the PAPMET trial! Though there is no significant OS difference, cabozantinib remains a solid option for advanced Papillary RCC. The need for novel therapies is clear! ASCO Journal of Clinical Oncology @oncoalert
So proud of Cristiane D Bergerot - after a stellar talk at #WCLC24, she is headed to #ESMO24 to educate us once again. Hard to find someone who works harder to advance #supportivecare. Neeraj Agarwal, MD, FASCO Petros Grivas Toni Choueiri, MD Shilpa Gupta Shuchi Gulati MD Matthew Loscalzo, LCSW City of Hope